HeartSyncÉlectrodes de défibrillation
Defibrillation, Cardioversion, Pacing, and ECG Monitoring
July 11, 2023 – Global Headquarters in Buffalo, NY - Nissha Medical Technologies (NMT) is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) for the HeartSync Defibrillation Electrodes.
The HeartSync Defibrillation Electrodes offer several key advantages over traditional defibrillation electrodes currently available on the market including:
This approval further reinforces the reputation of excellence associated with the products that we produce here at Nissha Medical Technologies.”, stated Peter O’Loughlin, Group Vice President. “We are proud that the HeartSync Defibrillation Electrodes were PMA approved by the FDA, and that we can continue to provide this lifesaving device to hospitals across the United States. HeartSync has a proven track record of clinical success, and this distinction is a clear indicator of that.”
Nissha Medical Technologies is a direct-to-hospital medical device manufacturer, and full-service product design and contract manufacturing partner, leveraging their global footprint and technical expertise to advance in various markets. Areas of specialization include product design & development, technology integration, vertical integration, and contract manufacturing of complex single-use minimally invasive surgical devices, complex clinical grade wearable devices, and an assortment of clinical accessories.
PMA Announcment - Press Release
Nissha Medical Technologies (NMT) is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) for the HeartSync Defibrillation Electrodes.
Last Edited: 01/01/0001
Nissha Medical Technologies propose de la documentation et des produits supplémentaires documents accessibles à tous les utilisateurs, gratuitement dans notre centre de téléchargement.Plus d'information